drugset
drugset / Trial / NCT04941989

A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562

NCT04941989 ↗

Phase 1 Terminated 33 enrolled Nxera Pharma UK Limited
RandomizedSequentialDouble-blindTreatment

Summary

Phase 1, randomised, double-blind, first in human, two part, single centre, placebo controlled, single and multiple ascending dose trial in healthy adult subjects to evaluate the safety, tolerability and pharmacokinetics of HTL0022562.

Timeline

Start
2021-05-25
Primary completion
2021-11-19
Completion
2021-11-19

Outcome

Outcome not reported

Stopped: “Early termination of study pending evaluation of emerging preclinical profile.”

Drugs

EvaluationDrugModalityDoseRoute
Subject HTL0022562 Small molecule — Subcutaneous

Indications

No indication recorded.